{"schema_version":"secwatch.filing_event.v1","accession":"0001818382-25-000073","form_type":"8-K","ticker":"HUMA","cik":"0001818382","company_name":"Humacyte, Inc.","filed_at":"2025-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.863324+00:00","generated_at":"2026-05-21T17:26:54.478804+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Humacyte posts Q1 net income $39.1M; Symvess launch generates $147K revenue","bullets":["Q1 2025 revenue $517K ($147K from first Symvess commercial sales); no revenue in Q1 2024.","Net income of $39.1M vs net loss of $31.9M YoY, driven by $62.3M non-cash remeasurement gain.","Cash and equivalents $113.2M; $46.7M net from March public offering extended runway.","Reduced workforce by ~31 employees; expects net savings of $13.8M in 2025, over $50M by 2026.","45 hospitals initiated Symvess VAC approval; 5 approved. On track for dialysis BLA in 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001818382-25-000073","json":"https://secwatch.observer/filing/0001818382-25-000073.json","markdown":"https://secwatch.observer/filing/0001818382-25-000073.md","text":"https://secwatch.observer/filing/0001818382-25-000073.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818382/000181838225000073/0001818382-25-000073-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818382/000181838225000073/huma-20250513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T17:26:54.478804+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}